ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |Omicron specific antibody Hot |Claudin 18.2 |Cadherin-17
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Protein > VEGF165 > VE5-H4210

Human VEGF165 Protein, premium grade

INTRODUCTION
QC & Assay Protocol
Citation & Background
  • Synonym
    RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF
  • Source
    Human VEGF165, premium grade(VE5-H4210) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4 ).
    Predicted N-terminus: Ala 27
    It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage. When ready to transition into later clinical phases, we also offer a custom GMP protein service that tailors to your needs. We will work with you to customize and develop a GMP-grade product in accordance with your requests that also meets the requirements for raw and ancillary materials use in cell manufacturing of cell-based therapies.
    Request for sequence
  • Molecular Characterization
    VEGF165 Structure

    This protein carries no "tag".

    The protein has a calculated MW of 19.2 kDa. The protein migrates as 24 kDa (monomer) under reducing (R) condition, and 43-50 kDa (homodimer) under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 0.1 EU per μg by the LAL method.
  • Host Cell Protein
    <0.5 ng/μg of protein tested by ELISA.
  • Host Cell DNA
    <0.02 ng/μg of protein tested by qPCR.
  • Sterility
    The sterility testing was performed by membrane filtration method.
  • Mycoplasma
    Negative.
  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 24 months in lyophilized state;
    2. -70°C for 24 months under sterile conditions after reconstitution.
SDS-PAGE
VEGF165 SDS-PAGE

Human VEGF165, premium grade on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
VEGF165 MALS images

The purity of Human VEGF165, premium grade (Cat. No. VE5-H4210) is more than 95% and the molecular weight of this protein is around 40-55 kDa verified by SEC-MALS.

Report
Bioactivity-Bioactivity CELL BASE
VEGF165 CELL

Human VEGF165, premium grade (Cat. No. VE5-H4210) stimulates proliferation of 293F-NFAT/Luc-VEGFR2-3-7 cells. The specific activity of Human VEGF165, premium grade is＞8.0*10^5 IU/mg, which is calibrated against human vascular endothelial growth factor 165 WHO International Standard (NIBSC code: 02/286) (QC tested).

Protocol
VEGF165 CELL

Human VEGF165, premium grade (Cat. No. VE5-H4210) stimulates proliferation of human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is 4.216-9.281 ng/mL (Routinely tested).

Protocol
VEGF165 CELL

Inhibition assay shows that the proliferation effect of Human VEGF165, premium grade (Cat. No. VE5-H4210) is inhibited by increasing concentration of anti-VEGF mAb (Avastin). The concentration of VEGF165 used is 20 ng/mL. The ED50 is 0.065-0.229 μg/mL (Routinely tested).

Protocol
VEGF165 CELL

Response to human VEGF165 protein (Fold).
The VEGFR2 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human VEGF165 protein (AcroBiosystems, Cat. No. VE5-H4210). The max induction fold was approximately 70 (Routinely tested).

Protocol
Bioactivity-ELISA
VEGF165 ELISA

Immobilized Human VEGF165, premium grade (Cat. No. VE5-H4210) at 0.1 μg/mL (100 μL/well) can bind Human VEGF R1 Protein, His Tag (Cat. No. VE1-H52H9) with a linear range of 1-10 ng/mL (QC tested).

Protocol
VEGF165 ELISA

Immobilized Human VEGF165, premium grade (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) with a linear range of 10-156 ng/mL (Routinely tested).

Protocol
VEGF165 ELISA

Immobilized Human VEGF165, premium grade (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Bevacizumab and 0.5 μg/mL (100 μL/well) Biotinylated Human VEGF R2, Avitag,His Tag (Cat. No. KDR-H82E5) with a half maximal inhibitory concentration (IC50) of 0.70 μg/mL (Routinely tested).

Protocol
Bioactivity-SPR
VEGF165 SPR

Avastin (Bevacizumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human VEGF165, premium grade (Cat. No. VE5-H4210) with an affinity constant of 0.776 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Protocol
Bioactivity-BLI
VEGF165 BLI

Loaded Avastin (Bevacizumab) on AHC Biosensor, can bind Human VEGF165, premium grade (Cat. No. VE5-H4210) with an affinity constant of 0.016 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol
VEGF165 BLI

Loaded Human NRP1, Fc Tag (Cat. No. NR1-H5252) on Protein A Biosensor, can bind Human VEGF165, Tag Free (Cat. No. VE5-H4210) with an affinity constant of 12.3 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol
VEGF165 BLI

Loaded Human VEGF R1, His Tag (Cat. No. VE1-H5220) on HIS1K Biosensor, can bind ActiveMax® Human VEGF165, Tag Free (Cat. No. VE5-H4210) with an affinity constant of 43.4 pM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol
  • Background
    VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.
  • Clinical and Translational Updates

  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : 64,120

価格(JPY) : 93,800

価格(JPY) : 644,000

一括購入 製品のカスタマイズ
Request GMP Version

プロモーション＆展示



医薬品開発状況

  • Number of Launched Drugs：35 Details
  • Number of Drugs in Clinical Trials：63 Details
  • Latest Research Phase：Approved
ほかの製品について

データシート＆ドキュメンテーション

DMF請求
DMF (Drug Master File)

お問い合わせ

+1  800-810-0816 (US)
+86 400-682-2521 (AP)
全ての代理店を表示する

関連製品一覧

新製品

お問い合わせ＆コメント

This web search service is supported by Google Inc.

totopphone
Call us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
日本：+(0)81-50-547-99099
Email
メールアドレス
order.jp@acrobiosystems.com
Fax
ファックス
+1 888-377-6111
Address
株式会社アクロバイオシステムズ
〒167‐0032
東京都杉並区天沼二丁目７番７号マンション大竹301　

アクロバイオシステムズの公式アカウント

linkedin twitter facebook youtube

お問い合わせ（半角英文字で入力してください）

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap